Buffett InvestorsNZX
Back
PEB.NZ

Pacific Edge Just Got Medicare Coverage in 13 More US States — Is the Worst Over?

A High-Stakes Turnaround With Real Catalysts

Pacific Edge (NZX: PEB) is one of the NZX's most polarising stocks. It's a Dunedin-based cancer diagnostics company with a genuinely innovative product — Cxbladder, a urine-based genomic test for detecting and monitoring bladder cancer. For years it was a growth darling. Then the US Medicare system pulled its reimbursement coverage, revenue collapsed, and the share price fell from highs above $0.30 to a 52-week low of $0.06.

Now, with a fresh Medicare coverage determination expanding access to 13 more western US states, the question is whether the worst is behind it — and whether the stock at around $0.11–0.12 NZD represents a real recovery opportunity or another false dawn.

What Happened — and What Just Changed

Pacific Edge's Cxbladder tests were previously covered by two major US Medicare Administrative Contractors (MACs): Palmetto and Noridian. Palmetto covers approximately 40% of the US Medicare population. In 2024, Noridian withdrew coverage for several Cxbladder tests, which hammered Pacific Edge's US revenue — its most important market — almost overnight.

The financial damage was immediate:

  • •H1 FY2026 operating revenue: $5.9M NZD (down from $10.9M in H2 FY2025)
  • •H1 FY2026 net loss: $19.1M NZD
  • •FY2024 full-year revenue: $22.75M NZD (down 9.8% year-on-year)

Then on March 18, 2026, the critical news arrived: Noridian issued a final local coverage determination restoring Cxbladder coverage across its jurisdiction — 13 western US states covering over 10 million Medicare beneficiaries. This follows an Expert Advisory Committee meeting in February where the evidence base for urine-based biomarker tests was formally acknowledged.

Why the Coverage Decision Matters So Much

Reimbursement is everything in US diagnostics. Without Medicare coverage, patients either can't access a test or face paying out of pocket — and most won't. With coverage, the test flows through the standard clinical pathway. Pacific Edge's entire US revenue engine runs on reimbursement status.

The Noridian reinstatement means:

  • •The key market that withdrew coverage has reversed its decision
  • •Both major US Medicare contractors now cover the core Cxbladder suite
  • •The commercial infrastructure Pacific Edge built in the US can be reactivated
  • •The newer Triage Plus test is priced at $1,328 per test — up from $760 for the prior generation, a significant per-unit revenue improvement

The most recent quarter showed test volumes of 5,582 (up 2.7% from Q3) — a small but genuine sign that volume is rebuilding.

Where the Stock Sits

  • •Share price: ~$0.11–0.12 NZD
  • •52-week high: $0.305 | 52-week low: $0.06
  • •Market cap: ~$174M NZD
  • •TTM revenue: $18.24M NZD
  • •Analyst average target: $0.128–0.16 NZD
  • •Analyst consensus: Neutral

The market cap of $174M against revenues of $18M implies the market is not yet pricing in a recovery — it's pricing in continued losses and uncertainty about whether the US rebuild sticks. That's either an opportunity or a reflection of justified scepticism.

The Bull Case

  • •Noridian coverage reinstatement removes the single biggest overhang on the stock
  • •Combined Palmetto + Noridian coverage now encompasses the majority of US Medicare beneficiaries
  • •Triage Plus at $1,328/test vs $760 prior means the same volume generates significantly more revenue
  • •Pacific Edge has a 13-year CAGR in test volumes of 31% — the underlying demand for better bladder cancer diagnostics is structural
  • •The Cxbladder suite recently won Best Oncology Presentation at the USANZ 2026 conference, reinforcing its clinical credibility

The Bear Case

  • •Revenue collapsed from a reimbursement decision once; it could happen again
  • •The company is burning cash with a $19.1M half-year loss — it will need the revenue to recover quickly or face capital requirements
  • •Analyst consensus is Neutral, not Buy — the market is not yet convinced the recovery will be fast enough
  • •This is a speculative, small-cap biotech stock with binary risk: if the US rebuild stalls, the share price could revisit its lows
  • •NZ is a tiny part of the revenue base; almost all growth depends on the US market executing

The Bottom Line

Pacific Edge is a genuine recovery story with a real catalyst — the Noridian Medicare coverage decision in March 2026 is the event the company needed. At ~$0.12 with a 52-week range of $0.06–$0.305, the stock reflects the uncertainty that remains. This is not a stock for conservative investors: the risk is real, the losses are ongoing, and execution in the US must now deliver. But for investors who understand the US diagnostics reimbursement landscape and believe in the Cxbladder clinical case, the coverage reinstatement changes the thesis meaningfully.

*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*